Moderna (NAS:MRNA) Debt-to-Equity

: 0.06 (As of Mar. 2023)

View and export this data going back to 2018. Start your Free Trial

Moderna's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $181 Mil. Moderna's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $927 Mil. Moderna's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $18,863 Mil. Moderna's debt to equity for the quarter that ended in Mar. 2023 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Moderna's Debt-to-Equity or its related term are showing as below:

MRNA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.06 Max: 0.11
Current: 0.06

During the past 7 years, the highest Debt-to-Equity Ratio of Moderna was 0.11. The lowest was 0.02. And the median was 0.06.

MRNA's Debt-to-Equity is ranked better than
68.19% of 1097 companies
in the Biotechnology industry
Industry Median: 0.14 vs MRNA: 0.06

Moderna Debt-to-Equity Historical Data

The historical data trend for Moderna's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

0.02

0.11

0.09

0.07

0.06

Moderna Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Equity																0.06	0.05	0.07	0.06	0.06

Competitive Comparison

For the Biotechnology subindustry, Moderna's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Moderna Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Moderna's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Moderna's Debt-to-Equity falls in comparison to its industry or sector. The grey bar indicates the Debt-to-Equity's extreme value range as defined by GuruFocus.

Moderna Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Moderna's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(196	+	1004)	/	19123
	=	0.06

Moderna's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(181	+	927)	/	18863
	=	0.06

Moderna (NAS:MRNA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Moderna Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Moderna's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (NAS:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MRNA:Peru MRNA:Mexico MRNA_KZ:Kazakhstan 0A45:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Executives

James M Mock	officer: Chief Financial Officer	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Arpa Garay	officer: Chief Commercial Officer	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Jorge M Gomez	officer: See Remarks	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Burton	officer: Chief Medical Officer	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Shannon Thyme Klinger	officer: Chief Legal Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Le Goff Corinne	officer: Chief Commercial Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth E Tallett	director	6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
David W Meline	officer: Chief Financial Officer	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Sandra Horning	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Paul Sagan	director	AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Israel Ruiz	director	C/O FORTIVE CORPORATION, 6920 SEAWAY BOULEVARD, EVERETT WA 98203
Tal Zvi Zaks	officer: Chief Medical Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115